Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Mahmood, Dana ^a   Grubbström, Maria ^b   Lundberg, Lennart D I ^b   Olivecrona, Gunilla ^c   Olivecrona, Thomas ^c   Stegmayr, Bernd G ^b  

^a Östersund Central Hospital   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TINZAPARIN; TRIACYLGLYCEROL; UREA; BIOLOGICAL MARKER; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG INFUSION; DRUG SUBSTITUTION; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID BLOOD LEVEL; MALE; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 78649694621     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-33     Document Type: Article

References (35)

1. Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. A Davenport, Nephrology (Carlton) 2009 14 5 455 461 10.1111/j.1440-1797.2009.01135.x 19674314
2. Low-molecular-weight heparin in patients with renal insufficiency. P Schmid AG Fischer WA Wuillemin, Swiss Med Wkly 2009 139 31-32 438 452 19685350
3. Biphasic effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. O Chevreuil M Hultin P Ostergaard T Olivecrona, Arterioscler Thromb 1993 13 10 1397 1403 8399075
4. Depletion of lipoprotein lipase after heparin administration. O Chevreuil M Hultin P Ostergaard T Olivecrona, Arterioscler Thromb 1993 13 10 1391 1396 8399074
5. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. B Nasstrom B Stegmayr J Gupta G Olivecrona T Olivecrona, Nephrol Dial Transplant 2005 20 6 1172 1179 10.1093/ndt/gfh774 15797889
6. Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. B Nasstrom BG Stegmayr G Olivecrona T Olivecrona, J Lab Clin Med 2003 142 2 90 99 10.1016/S0022-2143(03)00059-3 12960955
7. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. KE Ryan DA Lane A Flynn J Shepperd HA Ireland JR Curtis, Thromb Haemost 1991 66 3 277 282 1745997
8. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. HK Simpson J Baird M Allison JD Briggs PA Rowe M Welsh AI Macdougall AC Grant GD Lowe A Rumley, et al. Haemostasis 1996 26 2 90 97 9119288
9. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis. KA Al-Saran A Sabry M Taha MA Ghafour F Al Fawzan, Saudi J Kidney Dis Transpl 2010 21 1 43 49 20061691
10. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. JT Daugirdas, J Am Soc Nephrol 1993 4 5 1205 1213 8305648
11. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. JW Hainer DJ Sherrard SK Swan JS Barrett CA Assaid MJ Fossler DS Cox RM Williams AL Pittenger CA Stephenson, et al. Am J Kidney Dis 2002 40 3 531 538 10.1053/ajkd.2002.34911 12200805
12. Randomised long-term comparison of tinzaparin and dalteparin in haemodialysis. RJR Beijering Ht Cate P Stevens R Vanholder WTV Dorp RWv Olden B Wickstrom I Sprogel JWt Cate, Clin Drug Invest 2003 23 2 85 97 10.2165/00044011-200323020-00002 (Pubitemid 36286709)
13. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. H Lord N Jean M Dumont J Kassis M Leblanc, Am J Nephrol 2002 22 1 58 66 10.1159/000046675 11919404
14. Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. B Nasstrom B Stegmayr G Olivecrona T Olivecrona, BMC Nephrol 2004 5 1 17 10.1186/1471-2369-5-17 15527497
15. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis. M Egfjord L Rosenlund B Hedegaard HL Buchardt C Stengel P Gardar L Andersen L Andersen, Artif Organs 1998 22 8 633 637 10.1046/j.1525-1594.1998.06008.x 9702313
16. Heparin-decasaccharides impair the catabolism of chylomicrons. O Chevreuil M Hultin P Ostergaard T Olivecrona, Biochem J 1996 320 Pt 2 437 444 8973550
17. GPIHBP1 and lipolysis: an update. AP Beigneux MM Weinstein BS Davies P Gin A Bensadoun LG Fong SG Young, Curr Opin Lipidol 2009 20 3 211 216 10.1097/MOL.0b013e32832ac026 19369870
18. Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. F Karpe T Olivecrona A Hamsten M Hultin, J Lipid Res 1997 38 5 949 961 9186912
19. Acute effect of heparin on lipid parameters in patients on renal replacement therapy. KP Katopodis E Koliousi C Gouva O Balafa E Bairaktari M Ikonomou MS Elisaf KC Siamopoulos, Asaio J 2007 53 1 46 49 10.1097/01.mat. 0000247155.20214.20 17237649
20. Effects of conventional heparin and low-molecular-weight heparin treatment on lipid metabolism during a single hemodialysis session. T Camsari C Cavdar H Ozture B Onvural I Semin A Celik S Kavukcu, Nephron 1999 82 3 286 288 10.1159/000045418 10396006
21. Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis. T Akiba K Tachibana K Ozawa Y Chida H Ogasawara N Yoshiyama M Hoshino T Inada F Marumo, Asaio J 1992 38 3 326 330 10.1097/00002480-199207000-00047 1333845
22. Effects of heparin on the uptake of lipoprotein lipase in rat liver. L Neuger S Vilaro C Lopez-Iglesias J Gupta T Olivecrona G Olivecrona, BMC Physiol 2004 4 1 13 10.1186/1472-6793-4-13 15544705
23. Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role. S Vilaro M Llobera G Bengtsson-Olivecrona T Olivecrona, Am J Physiol 1988 254 5 Pt 1 711 722 3284386
24. Low molecular weight heparin - does it favourably affect lipid levels? P Stenvinkel, Nephrol Dial Transplant 1995 10 1 16 18 7724021
25. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides]. J Wiemer JE Scherberich, MMW Fortschr Med 1999 141 43 29 32 10912118
26. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Y Schmitt H Schneider, Nephrol Dial Transplant 1993 8 5 438 442 8393549
27. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. MS Elisaf NP Germanos HT Bairaktari MB Pappas EI Koulouridis KC Siamopoulos, Am J Nephrol 1997 17 2 153 157 10.1159/000169090 9096446
28. Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients. MS Elisaf H Bairaktari N Germanos M Pappas E Koulouridis N Papagalanis KC Siamopoulos, Int Angiol 1996 15 3 252 256 8971586
29. Long-term effect of low molecular weight heparin on serum lipids in hypertriglyceridemic chronic hemodialysis patients. D Vlassopoulos C Noussias A Hadjipetrou D Arvanitis E Logothetis P Magana K Katopodis V Hadjiconstantinou, J Nephrol 1997 10 2 111 114 9238618
30. Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long-term hemodialysis. JG Leu HH Liou SC Wu WC Yang TP Huang SC Wu, J Formos Med Assoc 1998 97 1 49 54 9481065
31. Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis. C Yang T Wu C Huang, Am J Nephrol 1998 18 5 384 390 10.1159/000013381 9730561
32. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. KN Lai K Ho RC Cheung LC Lit SK Lee KS Fung MK Tong CW Lam, Int J Artif Organs 2001 24 7 447 455 11510916
33. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. J Wiemer K Winkler M Baumstark W Marz JE Scherberich, Nephrol Dial Transplant 2002 17 12 2231 2238 10.1093/ndt/17.12.2231 12454238
34. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. F Kronenberg P Konig K Lhotta A Steinmetz H Dieplinger, Clin Nephrol 1995 43 6 399 404 7554525
35. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study. F Kronenberg P Konig U Neyer M Auinger A Pribasnig T Meisl G Pinter H Dieplinger, Thromb Haemost 1995 74 4 1025 1028 8560405